FeesSafety
Pluang+

Pemvidutide shows significant liver health improvements in 48-week MASH trial, advancing Phase 3 study.

Company Fundamentals
12 Nov 2026, 14:15 WIB
GlobeNewsWire
View Source
Bullish
Pemvidutide shows significant liver health improvements in 48-week MASH trial, advancing Phase 3 study.

Altimmune published 48-week Phase 2b trial results of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), showing significant reductions in liver fat, inflammation, fibrosis, and weight loss compared to placebo. The drug maintained glycemic control with a favorable safety profile and no major heart rate changes. These results support ongoing Phase 3 PERFORMA trial and highlight pemvidutide's potential as a new MASH treatment option.

Altimmune's recent publication of Phase 2b data for pemvidutide in MASH offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 84 rose and 57 fell. Notable movers include AVAH at USD 13.61 (+3.97%), INO at USD 1.43 (-3.05%) with 58% sell order activity, and MRVI at USD 7.93 (+2.99%).

More News

Tilray's 10 Barrel, Widmer Brothers, and Hop Valley named official craft beer partners of Portland Trail Blazers.

Tilray's 10 Barrel, Widmer Brothers, and Hop Valley named official craft beer partners of Portland Trail Blazers.

Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...

Market News
Bullish
33 minutes ago
Titan Mining's nine-month Adjusted EBITDA jumps 146% to $19.8M, advancing U.S. critical minerals projects.

Titan Mining's nine-month Adjusted EBITDA jumps 146% to $19.8M, advancing U.S. critical minerals projects.

Titan Mining reported a 146% increase in nine-month Adjusted EBITDA to $19.8 million, driven by a 38% rise in revenue to $67.9 million. Despite some production delays, zinc output is expected to improve in Q4 2026. The company is progressing its U.S....

Company Fundamentals
Bullish
1 hour ago
Nexpu completes delivery of 10,000 resale robots worth $4.8M under existing contract

Nexpu completes delivery of 10,000 resale robots worth $4.8M under existing contract

Nexpu Ltd.'s subsidiary, Top Kingwin Hi Tech Inc., has finished delivering all 10,000 TK-D2C robots to Walkers Times International under a $4.8 million resale contract signed in 2025. The deliveries were completed in batches, with the final 5,000 uni...

Market News
Bullish
1 hour ago
Katapult Holdings reports Q3 2026 results with $753.9M revenue, $110.4M adjusted EBITDA, and $30M cost synergies from merger.

Katapult Holdings reports Q3 2026 results with $753.9M revenue, $110.4M adjusted EBITDA, and $30M cost synergies from merger.

Katapult Holdings announced its third quarter 2026 financial results, reporting total revenues of $753.9 million and an adjusted EBITDA of $110.4 million, reflecting a 23% increase year-over-year on a combined basis. The company completed a merger wi...

Company Fundamentals
Neutral
1 hour ago
Three-quarters of U.S. workers plan to freelance within 3 years, valuing independence over salary.

Three-quarters of U.S. workers plan to freelance within 3 years, valuing independence over salary.

A new report from Fiverr reveals that 81% of full-time U.S. employees want to become their own boss, with 42% prioritizing independence over higher pay. This trend, dubbed "The Great Flexit," shows workers quietly preparing to freelance by building A...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App